Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting
Evoke Pharma (NASDAQ: EVOK) announced two upcoming poster presentations featuring Gimoti® nasal spray at the American College of Gastroenterology Annual Scientific Meeting in Philadelphia, October 25-29, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evoke Pharma (NASDAQ: EVOK) announced two upcoming poster presentations featuring Gimoti® nasal spray at the American College of Gastroenterology Annual Scientific Meeting in Philadelphia, October 25-29, 2024. One abstract, Poster P3339, received the ACG's Outstanding Research Award in the Stomach Category and the Presidential Poster Award, an honor given to less than 5% of submitted abstracts. The company will also showcase a new marketing campaign and expanded exhibit booth for GIMOTI at location #361.
Positive
- Received prestigious ACG Outstanding Research Award in Stomach Category
- Earned Presidential Poster Award (top 5% of submitted abstracts)
Negative
- None.
Details
News Market Reaction – EVOK
The recorded move for EVOK in the trading session of this news was -5.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOLANA BEACH, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced upcoming poster presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, held from October 25-29, 2024.
Evoke will feature two poster presentations highlighting the use of Gimoti® (metoclopramide) nasal spray in patients. Notably, one of these abstracts, Poster P3339, has been honored with the prestigious ACG’s Outstanding Research Award in the Stomach Category for the top abstract across this section of research. It has also been awarded the Presidential Poster Award—a distinction granted to fewer than
Poster Presentation Details:
- Poster Number: P1606
- Session Time: Sunday, October 27, 2024, 3:30 p.m. – 7:00 p.m. ET
- Presenting Authors: Richard McCallum, MD and Michael Cline, DO.
- Poster Number: P3339
- Session Time: Monday, October 28, 2024, 10:30 a.m. – 4:15 p.m. ET
- Presenting Author: David Kunkel, MD
Evoke will also exhibit at ACG, unveiling a newly expanded exhibit booth and introducing our new marketing campaign for GIMOTI. It will be prominently showcased at location #361 in the ACG Exhibit Hall. Please join members of the management and commercial team to learn more about GIMOTI.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Visit www.EvokePharma.com for more information.
Follow Evoke Pharma on LinkedIn
Follow Evoke Pharma on Twitter
Investor & Media Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.